| Biological Sciences | Lifetime | 851 | US 462 | 99.90 |
| Biological Sciences | 2021-2025 | 88 | US 13 | 99.92 |
| Medical and Health Sciences | 2021-2025 | 866 | US 301 | 99.80 |
| Genetics | Lifetime | 77 | US 43 | 99.83 |
| Epidemiology | Lifetime | 214 | US 109 | 99.73 |
| Infectious Diseases | Lifetime | 493 | US 255 | 98.09 |
| Gastroenterology | Lifetime | 312 | US 117 | 95.33 |
| Hepatology | Lifetime | 696 | US 254 | 88.36 |
| Genetics | 2021-2025 | 11 | US 4 | 99.83 |
| Epidemiology | 2021-2025 | 112 | US 32 | 99.30 |
| Surgery | 2021-2025 | 556 | US 216 | 95.36 |
| Immunology | 2021-2025 | 682 | US 243 | 78.92 |
| Inflammatory Bowel Disease | Lifetime | 20 | US 6 | 99.85 |
| Microscopic Colitis | Lifetime | 16 | US 6 | 99.84 |
| Eosinophilic Esophagitis | Lifetime | 49 | US 25 | 99.61 |
| Clostridium difficile and Clostridium perfringens research | Lifetime | 42 | US 16 | 99.48 |
| Pregnancy and Medication Impact | Lifetime | 34 | US 17 | 99.21 |
| Helicobacter pylori-related gastroenterology studies | Lifetime | 145 | US 52 | 99.23 |
| Autoimmune and Inflammatory Disorders | Lifetime | 37 | US 14 | 99.21 |
| Gut microbiota and health | Lifetime | 226 | US 92 | 99.16 |
| Diagnosis and treatment of tuberculosis | Lifetime | 98 | US 29 | 98.61 |
| Gastrointestinal motility and disorders | Lifetime | 178 | US 71 | 98.44 |
| Diverticular Disease and Complications | Lifetime | 185 | US 83 | 98.22 |
| Vitamin D Research Studies | Lifetime | 223 | US 106 | 98.22 |
| Colorectal Cancer Screening and Detection | Lifetime | 686 | US 302 | 97.60 |
| IL-33, ST2, and ILC Pathways | Lifetime | 381 | US 162 | 96.46 |
| Celiac Disease Research and Management | Lifetime | 526 | US 123 | 94.03 |
| Gastrointestinal Bleeding Diagnosis and Treatment | Lifetime | 754 | US 208 | 90.71 |
| Medical Coding and Health Information | Lifetime | 981 | US 374 | 66.05 |
| Hidradenitis Suppurativa and Treatments | Lifetime | 989 | US 287 | 64.08 |
| Inflammatory Bowel Disease | 2021-2025 | 13 | US 6 | 99.83 |
| Microscopic Colitis | 2021-2025 | 13 | US 7 | 99.78 |
| Eosinophilic Esophagitis | 2021-2025 | 75 | US 38 | 97.93 |
| Helicobacter pylori-related gastroenterology studies | 2021-2025 | 94 | US 28 | 96.63 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 26 | US 7 | 97.69 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 333 | US 113 | 96.78 |
| Gut microbiota and health | 2021-2025 | 485 | US 76 | 96.65 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 133 | US 52 | 92.98 |
| Frailty in Older Adults | 2021-2025 | 901 | US 185 | 88.23 |
| Clostridium difficile and Clostridium perfringens research | 2021-2025 | 498 | US 149 | 85.93 |
| Gastrointestinal motility and disorders | 2021-2025 | 447 | US 111 | 86.58 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 616 | US 214 | 79.60 |
| Celiac Disease Research and Management | 2021-2025 | 415 | US 61 | 77.74 |
| Healthcare cost, quality, practices | 2021-2025 | 803 | US 345 | 72.10 |
| Diagnosis and treatment of tuberculosis | 2021-2025 | 634 | US 92 | 69.37 |
